Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
LIBRETTO-531 is first ever Phase 3 trial in RET-mutant medullary thyroid cancer
Randomized trial will examine selpercatinib against standard of care in 400 patients with advanced or metastatic treatment-naïve RET-mutant medullary thyroid cancer
... Biopharmaceuticals, Oncology Eli Lilly, selpercatinib, RET-mutant, medullary thyroid cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Thyroid | Thyroid Cancer